Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease – Labiotech.eu (blog)
|
Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease
Labiotech.eu (blog) With this new deal, Allergan will access both CRISPR/Cas9 and CRISPR/Cpf1 versions of the technology. The great potential of the technology has spurred a fierce battle between two parties over the ownership of the technology's IP. Recently, the US … Allergan And Editas Medicine Enter Into R&D Alliance Allergan (AGN) and Editas Tie Up to Treat Eye Diseases Pre-Movers Stocks In Imitation: Allergan plc (NYSE:AGN), Endo International plc (NASDAQ:ENDP) |
